肿瘤坏死因子-α抑制剂与低血糖的真实世界药物警戒分析
本研究基于药物警戒数据,采用适应症聚焦的不比例分析,检测TNF-α抑制剂相关低血糖报告信号。共1086例低血糖报告,仅在银屑病适应症中整体类别出现不比例信号(ROR 1.20, 95%CI 1.02-1.41);特定药物中阿达木单抗在强直性脊柱炎、银屑病和类风湿关节炎及英夫利西单抗在银屑病中显示显著ROR,但调整混杂后仅阿达木单抗信号稳定。
要点
- TNF-α抑制剂相关低血糖总体报告信号有限,仅在银屑病适应症中显现。
- 阿达木单抗在强直性脊柱炎、银屑病和类风湿关节炎中显示显著不比例信号。
- 调整年龄、性别、糖尿病状态及合并用药后,仅阿达木单抗信号保持稳定。
核心结论
- 研究识别出TNF-α抑制剂与低血糖之间一些潜在药物警戒信号,需进一步验证。
研究设计与样本
- 基于药物警戒数据库的适应症聚焦不比例分析,计算报告比值比(ROR)及95%置信区间,并用逻辑回归调整年龄、性别、糖尿病状态和影响血糖的合并用药。
主要发现
- 共报告1086例TNF-α抑制剂相关低血糖不良反应。
- 炎症性肠病适应症中未发现低血糖不比例信号。
- TNF-α抑制剂整体在银屑病适应症中出现低血糖不比例信号(n=267, ROR 1.20, 95%CI 1.02-1.41)。
- 阿达木单抗在强直性脊柱炎(n=37, ROR 1.97, 95%CI 1.28-3.04)、银屑病(n=160, ROR 1.64, 95%CI 1.37-1.97)和类风湿关节炎(n=230, ROR 1.35, 95%CI 1.16-1.56)中ROR显著。
- 英夫利西单抗在银屑病中ROR显著(n=18, ROR 2.14, 95%CI 1.33-3.42)。
关键数值与推荐
- 银屑病适应症中TNF-α抑制剂整体低血糖ROR 1.20(95%CI 1.02-1.41)。
- 阿达木单抗在强直性脊柱炎ROR 1.97(95%CI 1.28-3.04),银屑病ROR 1.64(95%CI 1.37-1.97),类风湿关节炎ROR 1.35(95%CI 1.16-1.56)。
- 英夫利西单抗在银屑病ROR 2.14(95%CI 1.33-3.42)。
临床怎么用
- 临床使用TNF-α抑制剂时应关注低血糖风险,尤其阿达木单抗用于强直性脊柱炎、银屑病或类风湿关节炎的患者。
- 对合并糖尿病或使用影响血糖药物的患者,建议加强血糖监测。
局限性
- 研究为药物警戒数据库的不比例分析,信号需进一步验证。
- 调整混杂因素后仅阿达木单抗信号稳定,其他信号可能受 confounding 影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: An association between tumor necrosis factor (TNF)-α inhibitors and hypoglycemia has been detected in a few case reports and small case series; however, no relevant pharmacovigilance data have been published yet. OBJECTIVE: The objective of this study was to detect and characterize relevant safety signals between hypoglycemia and TNF-α inhibitor use. METHODS: Indication-focused disproportionality analysis was conducted to detect increased reporting of TNF-α-associated hypoglycemia compared with all other reports with the same indication during the same time period. Reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated to determine disproportionality. To reduce potential confounding factors, adjusted RORs were further calculated by logistic regression to control for age, sex, diabetes status, and concomitant drugs that potentially affect blood glucose levels. RESULTS: In all, 1086 adverse drug reactions related to TNF-α inhibitors were reported as 'hypoglycemia'. There were no disproportionality signals of hypoglycemia in TNF-α inhibitor users with indication of inflammatory bowel disease. When TNF-α inhibitors were considered as a class, disproportion for hypoglycemia only emerged in indication of psoriasis (n = 267, ROR 1.20, 95% CI 1.02-1.41). In further analyses of specific TNF-α inhibitor type, significant RORs for hypoglycemia were found in indication of rheumatic disease, including adalimumab in ankylosing spondylitis (n = 37, ROR 1.97, 95% CI 1.28-3.04), psoriasis (n = 160, ROR 1.64, 95% CI 1.37-1.97), and rheumatoid arthritis (n = 230, ROR 1.35, 95% CI 1.16-1.56) and infliximab in psoriasis (n = 18, ROR 2.14, 95% CI 1.33-3.42). After adjusting for confounding factors, only the signals of adalimumab were stable. CONCLUSIONS: Our study identified some potential pharmacovigilance signals between hypoglycemia and TNF-α inhibitors, which warrants further validation.
引用
- Zhou Y, Xie W, Wang L, et al. Anti-tumor Necrosis Factor-Alpha Therapy and Hypoglycemia: A Real-World Pharmacovigilance Analysis. Drug Saf. 2022. PMID: 35857191. doi:10.1007/s40264-022-01210-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。